STOCK TITAN

Novavax, Inc. - NVAX STOCK NEWS

Welcome to our dedicated news page for Novavax (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novavax's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novavax's position in the market.

-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences
-
Rhea-AI Summary
Novavax announces expansion of authorization for Nuvaxovid COVID-19 vaccine in Switzerland for adolescents and booster doses in adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.19%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
covid-19
Novavax, Inc.

Nasdaq:NVAX

NVAX Rankings

NVAX Stock Data

668.98M
125.20M
5%
56.32%
34.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Gaithersburg

About NVAX

novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"​), seasonal influenza, pandemic influenza, and ebola virus ("ebov"​). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.